Drugs Containing Excipient (Inactive Ingredient) HYDROXYPROPYLBETADEX

« Back to Dashboard

Branded drugs containing HYDROXYPROPYLBETADEX excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Theravance Inc	VIBATIV	telavancin hydrochloride	52118-001	HYDROXYPROPYLBETADEX	2027-01-01

Generic drugs containing HYDROXYPROPYLBETADEX excipient

Company	Ingredient	NDC	Excipient
Theravance Inc	telavancin hydrochloride	52118-001	HYDROXYPROPYLBETADEX

Hydroxypropylbetadex Market Dynamics and Financial Trajectory

Last updated: September 27, 2026

Hydroxypropylbetadex, also called hydroxypropyl-beta-cyclodextrin or HPβCD, is a modified cyclodextrin used primarily to improve the aqueous solubility, stability, bioavailability, and processability of poorly soluble active pharmaceutical ingredients. Its commercial outlook is positive but specialized. Demand is tied to pharmaceutical formulation activity rather than direct consumer exposure, with growth concentrated in injectable, oral, ophthalmic, and research-stage products.

The market has favorable technical fundamentals, but financial visibility is limited because leading suppliers generally report cyclodextrin revenue within broader excipient or specialty-chemical segments. Publicly available data does not support a reliable standalone global market-size estimate or supplier-by-supplier revenue ranking.

What is hydroxypropylbetadex used for in pharmaceutical formulations?

Hydroxypropylbetadex is a nonionic, water-soluble beta-cyclodextrin derivative. Its hydrophobic internal cavity can form inclusion complexes with poorly water-soluble drug molecules, while its hydrophilic exterior improves dispersion in aqueous media.

Primary pharmaceutical uses include:

Application	Formulation role	Commercial relevance
Oral solid and liquid dosage forms	Solubility enhancement and dissolution improvement	High
Parenteral products	Solubilization of injectable drugs	High but subject to safety and impurity controls
Ophthalmic products	Drug solubilization and formulation stabilization	Moderate
Nasal and mucosal delivery	Solubility and permeability modification	Development-stage
Topical products	Solubility and controlled release	Selective
Drug discovery	Screening and preformulation of insoluble compounds	Recurring laboratory demand
Biotechnology and specialty research	Cholesterol complexation and membrane studies	Smaller, specialized segment

HPβCD differs from sulfobutylether-beta-cyclodextrin, marketed in some products under the Captisol brand. The two excipients have different chemical structures, regulatory histories, safety profiles, supplier positions, and commercial applications. Substitution is formulation-specific and usually requires new compatibility, toxicology, stability, and regulatory work.

How does hydroxypropylbetadex improve drug performance?

HPβCD improves apparent solubility by forming reversible complexes with hydrophobic portions of drug molecules. The effect depends on the drug’s molecular size, polarity, dose, complexation constant, formulation pH, and the concentration of HPβCD.

The principal value proposition is formulation enablement. HPβCD can allow a development team to:

• reduce precipitation risk after dilution;
• improve dissolution and early exposure;
• reduce the quantity of organic cosolvent or surfactant;
• support liquid formulations of compounds that otherwise require suspensions;
• improve the physical stability of some drug substances;
• simplify development of injectable or ophthalmic dosage forms.

Its limitations are equally important. High excipient concentrations may increase osmolality, viscosity, manufacturing cost, and container-closure compatibility risk. Complexation can also reduce free-drug concentration, which may affect permeability and pharmacokinetics. The excipient is therefore selected after a formulation trade-off, not solely on the basis of solubility gain.

What drives demand for hydroxypropylbetadex?

Demand is linked to four structural pharmaceutical trends.

Poor aqueous solubility in drug pipelines

A large share of small-molecule development candidates has limited aqueous solubility. Cyclodextrins are among several formulation tools used to address this problem, alongside amorphous solid dispersions, lipid systems, nanosuspensions, surfactants, salts, cocrystals, and particle-size reduction.

HPβCD is most valuable when the active ingredient needs a liquid formulation or when conventional solid-dispersion methods are unsuitable.

Growth in injectable reformulation

Injectable development creates a higher-value opportunity because solubilizing excipients can determine whether a compound reaches a usable concentration without excessive cosolvent or surfactant. This segment has stricter requirements for endotoxin, bioburden, residual solvents, elemental impurities, extractables, and toxicological qualification.

Lifecycle management

Sponsors may use HPβCD in reformulations intended to improve dissolution, reduce dosing volume, create an oral liquid, develop a pediatric presentation, or extend the usable shelf life of a product. These applications can create demand even after the active pharmaceutical ingredient loses market exclusivity.

Outsourced formulation development

Contract development and manufacturing organizations frequently purchase specialty excipients for feasibility studies, clinical batches, and commercial manufacture. This broadens the customer base beyond originator companies and supports recurring laboratory and small-batch demand.

What is the regulatory status of hydroxypropylbetadex?

HPβCD is regulated as an excipient rather than as an independently approved active drug. Its acceptability depends on route, concentration, grade, impurities, manufacturing controls, and the specific finished product.

The regulatory assessment usually addresses:

• chemical substitution level;
• degree of polymerization and molecular-weight distribution;
• residual solvents;
• related cyclodextrins and unreacted starting materials;
• elemental impurities;
• microbial quality and endotoxins;
• stability and degradation products;
• route-specific toxicology;
• compatibility with the active ingredient and container system.

The FDA Inactive Ingredient Database is a key reference for determining whether an excipient has prior use in a particular route and dosage form. A prior listing does not create blanket approval for all concentrations or routes. New or materially different use may require additional justification in an abbreviated or full regulatory submission.[1]

European applicants typically assess excipients under European Pharmacopoeia requirements, national or European regulatory guidance, and route-specific safety expectations. The European Medicines Agency’s excipient guidance emphasizes quality, safety, and justification of excipient use in the finished medicinal product.[2]

What is the Orange Book status of hydroxypropylbetadex?

Hydroxypropylbetadex does not have an independent FDA Orange Book listing because the Orange Book covers approved drug products and their patent and exclusivity information, not commodity excipients sold as standalone formulation ingredients.[3]

The relevant regulatory and commercial protections are instead found in:

• finished-drug patents;
• formulation patents;
• method-of-use patents;
• manufacturing-process patents;
• supplier specifications;
• regulatory drug-master-file or master-file strategies;
• quality agreements and customer qualification records.

An HPβCD supplier cannot rely on Orange Book exclusivity to protect sales. Its competitive position depends on quality consistency, regulatory history, technical support, capacity, and customer qualification.

What patents protect hydroxypropylbetadex?

The basic concept of beta-cyclodextrin and hydroxypropylated derivatives is established technology. Broad composition claims directed to the general class are unlikely to provide a strong basis for exclusive control of the commodity market.

Patent value is more likely to arise from:

1. specific substitution patterns or molecular-weight distributions;
2. high-purity manufacturing processes;
3. methods for removing residual reagents and byproducts;
4. drug-HPβCD complexes;
5. injectable, ophthalmic, or pediatric formulations;
6. specific dosage regimens;
7. stabilization or lyophilization processes;
8. combination systems involving HPβCD and other solubilizers.

A freedom-to-operate assessment must distinguish the excipient itself from a patented finished formulation. A drug company may be free to purchase and use HPβCD while still facing infringement risk from a formulation patent covering the combination of the active ingredient and cyclodextrin.

Are Paragraph IV challenges relevant?

Paragraph IV litigation is generally not directed at HPβCD as an independent product. It becomes relevant when a generic drug applicant challenges patents listed for a finished drug that uses HPβCD or another cyclodextrin in its formulation.

The commercial outcome depends on whether the listed patent claims:

• the active ingredient;
• the dosage form;
• the HPβCD-containing formulation;
• a method of treating a disease;
• a concentration or release profile.

An excipient supplier is usually not the primary litigant in such cases, although supplier documents and technical specifications can become relevant to infringement, invalidity, or product-development evidence.

How strong is the hydroxypropylbetadex patent estate?

The patent estate is fragmented rather than concentrated.

IP category	Likely strength	Commercial impact
Basic HPβCD composition	Low to moderate for new market control	Limited
Purity and manufacturing process	Moderate	Relevant where quality is difficult to replicate
Drug-specific complex	Moderate to strong	Can protect individual products
Injectable formulation	Moderate to strong	Potentially important for branded products
Ophthalmic formulation	Moderate	Depends on claim scope
Generic supplier process	Variable	Often protected as know-how rather than broad patents
Trade secret manufacturing controls	High operational value	Important for consistency and scale-up

The most defensible supplier advantages may not be patent claims. They can include validated manufacturing processes, consistent substitution profiles, low impurity levels, regulatory documentation, global supply qualification, and the ability to produce clinical and commercial quantities.

Which companies supply hydroxypropylbetadex?

The commercial supply base includes specialist cyclodextrin manufacturers and diversified excipient companies. Known market participants include Wacker Chemie, Roquette, CycloLab, and other regional producers and distributors. Wacker markets hydroxypropyl-beta-cyclodextrin under its CAVASOL product family, while Roquette markets cyclodextrin-based pharmaceutical excipients under the Kleptose brand family.[4,5]

Supplier competition is based on more than nominal price. Buyers compare:

• pharmaceutical-grade documentation;
• batch-to-batch substitution consistency;
• availability of GMP production;
• analytical method support;
• regulatory filing packages;
• geographic supply continuity;
• lead time and minimum order quantity;
• ability to support clinical-to-commercial scale-up.

Customer switching costs rise after an excipient is incorporated into a registered product. A change in supplier may require comparative testing, stability work, regulatory notification, and requalification of manufacturing processes.

How does hydroxypropylbetadex compare with competing excipients?

Excipient	Main advantage	Main limitation	Typical competitive position
HPβCD	Strong aqueous solubility and broad formulation utility	Dose, osmolality, cost, and route-specific safety considerations	Flexible specialty option
Sulfobutylether-beta-cyclodextrin	Strong parenteral solubilization history in certain products	Proprietary supply and product-specific commercial positioning	High-value injectable alternative
Methyl-beta-cyclodextrin	Strong hydrophobic complexation	Greater safety limitations for systemic use	Research and selected local applications
Polysorbates	Low cost and established use	Oxidation, hydrolysis, and protein compatibility concerns	Common protein and injectable excipient
PEG and propylene glycol	Simple liquid cosolvent systems	Toxicity, tolerability, and dose-volume limitations	Widely used conventional option
Amorphous solid dispersions	Effective for oral bioavailability	Manufacturing complexity and physical stability risk	Major oral formulation competitor
Lipid-based systems	Useful for highly lipophilic drugs	Emulsion, capsule, and scale-up requirements	Strong oral and parenteral alternative

HPβCD is most competitive where a sponsor needs a relatively clean aqueous formulation and wants to avoid high levels of organic cosolvents or surfactants.

What is the financial trajectory for hydroxypropylbetadex?

The financial trajectory is best characterized as steady specialty-excipient growth rather than explosive commodity expansion.

Near-term outlook

Near-term demand should remain supported by:

• preclinical and clinical formulation work;
• injectable reformulation programs;
• specialty oral liquids;
• ophthalmic development;
• rising use of outsourced development services;
• demand for higher-purity and regulatory-ready grades.

Revenue growth is likely to be uneven because individual commercial launches can create large volume increases for a supplier, while many development programs remain small or fail before approval.

Medium-term outlook

Medium-term growth depends on product conversion. HPβCD demand increases materially when a clinical formulation reaches commercial manufacture. Development-stage consumption alone is less valuable because batch sizes are small and programs have high attrition.

The strongest commercial opportunities are likely to come from:

• approved products requiring persistent solubility enhancement;
• complex generic formulations;
• pediatric and geriatric liquid products;
• specialty injectables;
• products with limited alternatives for aqueous delivery.

Margin outlook

Margins should remain above those of standard commodity excipients when the supplier provides pharmaceutical-grade documentation, technical services, and route-specific support. Margin pressure can arise from:

• additional Asian capacity;
• customer concentration;
• normalization of freight and energy costs;
• substitution by solid-dispersion or lipid technologies;
• price negotiations after a product becomes commercially mature.

High-purity injectable grades should command the strongest pricing. Research grades and non-sterile oral grades face greater competition.

What generic entry risks exist for drugs using hydroxypropylbetadex?

Generic entry risk is product-specific. The presence of HPβCD does not by itself create a durable barrier to generic competition.

Risk increases when:

• the formulation patent claims a narrow HPβCD-to-drug ratio;
• the drug has poor solubility and few viable formulation alternatives;
• bioequivalence depends on complexation behavior;
• the product is an injectable or ophthalmic formulation;
• the reference product has a difficult-to-reproduce particle, viscosity, or release profile;
• supplier changes affect substitution level or impurity profile.

Risk decreases when a generic can use a different solubilization technology or demonstrate bioequivalence through a conventional route.

What is the competitive landscape for hydroxypropylbetadex?

The competitive landscape has three layers:

1. Global specialty suppliers with pharmaceutical documentation and multinational customer access.
2. Regional manufacturers competing on price, capacity, and lead time.
3. Technology substitutes competing at the formulation level rather than the excipient level.

Supplier concentration is likely higher for validated injectable and high-purity material than for research or lower-grade products. Qualification barriers protect incumbents after a customer has approved a supplier, but they do not prevent substitution during early development.

Key Takeaways

• HPβCD is a specialty pharmaceutical excipient used primarily for solubility enhancement.
• Its strongest commercial applications are injectable, oral-liquid, ophthalmic, and development-stage formulations.
• The market has favorable demand drivers but limited transparent standalone financial reporting.
• Wacker, Roquette, CycloLab, and regional manufacturers compete on quality, regulatory support, capacity, and price.
• Basic HPβCD composition patents are unlikely to control the commodity market.
• The most valuable IP is found in drug-specific formulations, manufacturing processes, and technical know-how.
• HPβCD has no independent Orange Book exclusivity.
• Paragraph IV risk applies to finished drug patents, not usually to the excipient itself.
• Financial growth should be tied to commercial product launches rather than laboratory consumption alone.
• The principal competitive threat is substitution by sulfobutylether-beta-cyclodextrin, solid dispersions, lipid systems, surfactants, and other solubilization technologies.

FAQs

Is hydroxypropylbetadex the same as Captisol?

No. Hydroxypropylbetadex is hydroxypropyl-beta-cyclodextrin. Captisol is a brand associated with sulfobutylether-beta-cyclodextrin. They have different chemical structures and commercial positions.

Is hydroxypropylbetadex suitable for injectable drugs?

It can be used in injectable formulations when the grade, concentration, impurities, endotoxin profile, toxicology, and finished-product performance are acceptable to regulators.

Does hydroxypropylbetadex have a standalone pharmaceutical patent?

The general technology is established. Current commercial protection is more likely to involve specific manufacturing processes, purity profiles, drug complexes, or finished formulations than a broad standalone composition patent.

Can a generic drug manufacturer freely substitute one HPβCD supplier for another?

No. Supplier substitution may require comparative testing, qualification, stability assessment, and regulatory review, particularly for sterile or injectable products.

What determines the price of pharmaceutical-grade HPβCD?

Price is driven by substitution profile, purity, production scale, GMP controls, documentation, packaging, order volume, delivery requirements, and whether the material is intended for clinical, commercial, injectable, or research use.

References

1. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. FDA. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

2. European Medicines Agency. (2017). Guideline on the excipients in the dossier for application for marketing authorisation of a medicinal product. EMA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

4. Wacker Chemie AG. (n.d.). CAVASOL cyclodextrins for pharmaceutical applications. Wacker.

5. Roquette. (n.d.). KLEPTOSE pharmaceutical excipients. Roquette.

6. National Center for Biotechnology Information. (n.d.). PubChem compound summary: Hydroxypropyl-beta-cyclodextrin. PubChem. https://pubchem.ncbi.nlm.nih.gov/

7. International Council for Harmonisation. (2009). ICH Q8(R2): Pharmaceutical development. ICH.